Orgenesis reaches next milestone in collaboration with Spanish hospital

27 January 2022

US biotech firm Orgenesis (Nasdaq: ORGS) today announces it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Nino Jesus (Hospital) in Madrid, Spain.

The milestone has been achieved by completing the placement of an Orgenesis Mobile Processing Unit and Lab (OMPUL) on site. This OMPUL is the first in Europe that has been designed specifically to process tumor infiltrating lymphocytes (TILs) and mesenchymal stem cells (MSCs). OMPULs are multi-purpose mobile autonomous good manufacturing practice (GMP) facilities intended to develop, optimize and process cell and gene therapies at the point of care.

Orgenesis first signed a research and development collaboration with Hospital Infantil Universitario Niño Jesús in May 2020, which was established to create a point-of-care center (POCare). The OMPUL was delivered in January 2022 and is expected to be operational following certification by the Spanish health authorities and regulatory bodies, which is anticipated in second-quarter 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK